Consumer health: What is lung cancer screening, and who needs it?

by Laurel KellyCredit: Pixabay/CC0 Public DomainLung cancer is the leading cause of cancer deaths in the U.S., according to the American Cancer Society. Lung cancer claims more lives each year than co

Updated on: December 18,2023

Consumer health: What is lung cancer screening, and who needs it?

by Laurel KellyCredit: Pixabay/CC0 Public DomainLung cancer is the leading cause of cancer deaths in the U.S., according to the American Cancer Society. Lung cancer claims more lives each year than co

Updated on:December 18,2023

Developing therapies for treatment-resistant prostate cancer: Small clinical trial shows 40% progression-free survival

byCedars-Sinai Medical CenterGraphical abstract. Credit:Molecular Therapy(2022). DOI: 10.1016/j.ymthe.2022.08.019Investigators from Cedars-Sinai Cancer have identified an investigati

Updated on: December 26,2023

Developing therapies for treatment-resistant prostate cancer: Small clinical trial shows 40% progression-free survival

byCedars-Sinai Medical CenterGraphical abstract. Credit:Molecular Therapy(2022). DOI: 10.1016/j.ymthe.2022.08.019Investigators from Cedars-Sinai Cancer have identified an investigati

Updated on:December 26,2023

Mechanism for silencing gene expression targets the culprit behind a deadly liver cancer

by Sanford M. Simon,Rockefeller UniversityASGR1 in FLC. (A) RNA expression analysis of ASGR1 across patient samples. (B) Immunofluorescence of ASGR1 in tumor-adjacent healthy liver, primary tumo

Updated on: March 20,2024

Mechanism for silencing gene expression targets the culprit behind a deadly liver cancer

by Sanford M. Simon,Rockefeller UniversityASGR1 in FLC. (A) RNA expression analysis of ASGR1 across patient samples. (B) Immunofluorescence of ASGR1 in tumor-adjacent healthy liver, primary tumo

Updated on:March 20,2024

Novel combination therapy has similar response rates to chemotherapy for high-risk luminal B breast cancer

byAmerican Association for Cancer ResearchNeoadjuvant treatment with the CDK4/6 inhibitor ribociclib (Kisqali) and the aromatase inhibitor letrozole (Femara) produced response rates similar to m

Updated on: December 22,2023

Novel combination therapy has similar response rates to chemotherapy for high-risk luminal B breast cancer

byAmerican Association for Cancer ResearchNeoadjuvant treatment with the CDK4/6 inhibitor ribociclib (Kisqali) and the aromatase inhibitor letrozole (Femara) produced response rates similar to m

Updated on:December 22,2023

Time of death or personal autonomy? Cancer patients prefer knowing functional prognosis over life expectancy

byUniversity of TsukubaCredit: AI-generated imageProviding prognostic information is a vital component of cancer patient care. However, the specific information cancer patients prefer to receive

Updated on: January 04,2024

Time of death or personal autonomy? Cancer patients prefer knowing functional prognosis over life expectancy

byUniversity of TsukubaCredit: AI-generated imageProviding prognostic information is a vital component of cancer patient care. However, the specific information cancer patients prefer to receive

Updated on:January 04,2024

AI can be used to detect and grade prostate cancer

byKarolinska InstitutetMicrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia,CC BY-SA 3.0Researchers at Karolinska Institutet in Sw

Updated on: December 22,2023

AI can be used to detect and grade prostate cancer

byKarolinska InstitutetMicrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia,CC BY-SA 3.0Researchers at Karolinska Institutet in Sw

Updated on:December 22,2023

Survival in Primary Hemophagocytic Lymphohistiocytosis Can Be as High as 100%

February 2024Lara C. Pullen, PhDResults from a contemporary standard-of-care study of patients with primary hemophagocytic lymphohistiocytosis (pHLH) reveal that firstline etoposide-based therapy is m

Updated on: February 18,2024

Survival in Primary Hemophagocytic Lymphohistiocytosis Can Be as High as 100%

February 2024Lara C. Pullen, PhDResults from a contemporary standard-of-care study of patients with primary hemophagocytic lymphohistiocytosis (pHLH) reveal that firstline etoposide-based therapy is m

Updated on:February 18,2024

Researchers clarify role of SMYD3 enzyme in prostate cancer progression

by Sarah Hansen,University of Maryland Baltimore CountySMYD3 loss impedes PCa progression.(A) Expression ofSMYD3mRNA from TCGA [GTEX normal (n= 105), TCGA tumor adjacent normal

Updated on: December 26,2023

Researchers clarify role of SMYD3 enzyme in prostate cancer progression

by Sarah Hansen,University of Maryland Baltimore CountySMYD3 loss impedes PCa progression.(A) Expression ofSMYD3mRNA from TCGA [GTEX normal (n= 105), TCGA tumor adjacent normal

Updated on:December 26,2023

Olaparib maintenance extends PFS by estimated three years in advanced ovarian cancer

byEuropean Society for Medical OncologyTwo-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor, olaparib, led to a substantial, unprecedented improvement in pro

Updated on: December 18,2023

Olaparib maintenance extends PFS by estimated three years in advanced ovarian cancer

byEuropean Society for Medical OncologyTwo-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor, olaparib, led to a substantial, unprecedented improvement in pro

Updated on:December 18,2023

NELSON trial protocol more sensitive than NLST and may increase the benefits of lung cancer screening

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe protocol used to screen and detect lung cancer in the NELSON Trial is more sensitive than the protocol use

Updated on: December 18,2023

NELSON trial protocol more sensitive than NLST and may increase the benefits of lung cancer screening

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe protocol used to screen and detect lung cancer in the NELSON Trial is more sensitive than the protocol use

Updated on:December 18,2023

Drugs for treating breast cancer in women are effective and well tolerated in men

byEuropean Society for Medical OncologyThere is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated in men, according to the la

Updated on: December 18,2023

Drugs for treating breast cancer in women are effective and well tolerated in men

byEuropean Society for Medical OncologyThere is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated in men, according to the la

Updated on:December 18,2023

Scientists identify potential drug target for BRCA-mutated tumours

byInstitute of Cancer ResearchCrystal structure of EXD2 exonuclease domain in spacefill format. Credit: Image generated fromPDBA new study has uncovered a previously unknown role for the e

Updated on: December 22,2023

Scientists identify potential drug target for BRCA-mutated tumours

byInstitute of Cancer ResearchCrystal structure of EXD2 exonuclease domain in spacefill format. Credit: Image generated fromPDBA new study has uncovered a previously unknown role for the e

Updated on:December 22,2023